Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

Latest News

China's Xiaomi plans to raise up to $6.1 billion in Hong Kong IPO: sources

Jun 20, 2018

By Fiona Lau and Julie ZhuHONG KONG (Reuters/IFR) - Chinese smartphone maker Xiaomi is planning to raise up to $6.1 billion from a Hong Kong IPO launching this week, people with knowledge of the matter said, in what will be one of the biggest tech floats globally of recent years.Xiaomi, which also makes internet-connected devices, plans to sell about 2.18 billion shares in its initial public offering (IPO) at a price range of HK$17 to HK$22 ($2.17 to $2.80) each, said the people, who declined to be identified as the information was not public.The company plans to bring in eight...

World Cup games to air on free TV amid problems in Australia

Jun 20, 2018

SYDNEY — Rather than risk further outrage from football fans, rights holders in Australia have agreed to keep sharing World Cup matches with free-to-air TV until the end of the group stage. Telecommunications company Optus bought the broadcast rights for most World Cup games in Russia but technical issues with the live streaming in Australia caused a major backlash from subscription buyers — to the point where the prime minister had to intervene. The SBS network, which retained the broadcasting rights for Australia's games and the World Cup final under a sharing agreement with Optus for the 2018 tournament, initially...

ZTE's Hong Kong shares rise after clarification of U.S. bill impact

Jun 20, 2018

By Sijia JiangHONG KONG (Reuters) - Shares of China's ZTE Corp rose as much as 18 percent in Hong Kong on Wednesday as the impact of a U.S. Senate bill that threatens to restore penalties on the company became clearer.In clarification announcements during the noon trading break, ZTE said a National Defense Authorization Act (NDAA) passed by the U.S. Senate on Monday would restore penalties on the company, but the bill would only become law if it could be reconciled with a different version passed by the House of Representatives and signed by U.S. President Trump.That echoed what the White...

Survey: Companies in China feel pressure to give up tech

Jun 20, 2018

BEIJING — One in five foreign companies in China feels compelled to hand over technology for market access, a business group said Wednesday, highlighting a key irritant in an escalating U.S.-Chinese trade dispute. The European Union Chamber of Commerce in China's report follows President Donald Trump's order for tariffs on additional Chinese goods in response to complaints Beijing steals or pressures companies to hand over technology. Out of 532 European companies that responded to a survey, 19 percent "felt compelled to transfer technology in exchange for market access" despite Chinese assurances that it isn't required, the chamber said. "China has...

Australia's Telstra slashes jobs as 'tipping point' forces strategic reset

Jun 20, 2018

By Tom WestbrookSYDNEY (Reuters) - Australia's largest telecom firm Telstra Corp Ltd said it would cut a quarter of its workforce and flagged asset sales on Wednesday, as competition and new technology crush its mainstay fixed-line businesses and force a strategic reset.It will shed 8,000 employees and contractors from a workforce of 32,000 to save A$1 billion ($738 million), drop underperforming products and separate assets it values at A$11 billion from the rest of the firm.It also flagged a fall in 2019 earnings to between A$8.7 billion and A$9.4 billion, excluding restructuring costs of about A$600 million, having already warned...

Sign up now!